Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06034327 · ClinicalTrials.gov registry record · NA

Efficacy in Controlling Myopia in Young Children Using a Novel Spectacle Lens

A NA study of Myopia and Juvenile Myopia, sponsored by SightGlass Vision.

Recruiting
Registry status
NA
Development phase
150
Enrollment target
14
Study locations

NCT06034327: Recruiting NA study of Myopia and Juvenile Myopia, sponsored by SightGlass Vision.

NCT06034327 is a NA study of Myopia and Juvenile Myopia that is actively recruiting participants, run by SightGlass Vision. The registered enrollment target is 150 participants, below the 266-participant average among 90 other Myopia trials with a reported enrollment target (44% lower). The trial reports 14 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06034327, a NA study of Myopia and Juvenile Myopia, is actively recruiting participants, sponsored by SightGlass Vision.

RECRUITING
Registry status
NA
Development phase
150 participants
Enrollment target
14
Study locations

Study Summary

This is a conventional efficacy trial to validate the results from previous clinical trials for younger children; the 12-month efficacy results will be used to predict the 3-year treatment efficacy. This is a randomized, controlled (1:1), multisite, subject- and observer-masked, 2-arm parallel group study.

Primary Outcome

Change in spherical equivalent refraction from baseline

Interventions

  • DEVICE Single vision, impact-resistant spectacle lenses; Test Arm
  • DEVICE Single vision, impact-resistant spectacle lenses; Control Arm

Study Locations (14)

California

  • Elsa Pao, OD - Oakland
  • Scripps Poway Eyecare - San Diego
  • Pacific Rims Optometry - San Francisco
  • Paje Optometric - Santa Ana

Ohio

  • Athens Eye Care - Athens
  • Procare Vision Centers, Inc. - Granville

Texas

  • Texas State Optical - Dowlen - Beaumont
  • Bellaire Family Eye Care - Bellaire

Florida

  • Omega Vision Center - Longwood

Georgia

  • Marietta Eye Clinic - Marietta

Illinois

  • Ilinois College of Optometry - Chicago

Kansas

  • Kannarr Eye Care - Pittsburg

Massachusetts

  • New England College of Optometry - Boston

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2023-09-18
Est. Completion 2027-03-31
Phase NA
SightGlass Vision

8 total trials

What NCT06034327 shows while recruiting

NCT06034327 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 266-participant average among 90 other Myopia trials with a reported enrollment target (44% lower).

The record links to 3 conditions, with Myopia appearing as the primary indexed condition, and to 2 interventions - of which Single vision, impact-resistant spectacle lenses; Test Arm is the first listed.

NCT06034327 lists 14 locations in 9 states (California, Ohio, Texas).

Frequently Asked Questions

What is clinical trial NCT06034327 about?

NCT06034327 is a clinical study titled "Efficacy in Controlling Myopia in Young Children Using a Novel Spectacle Lens". This is a conventional efficacy trial to validate the results from previous clinical trials for younger children; the 12-month efficacy results will be used to predict the 3-year treatment efficacy. This is a randomized, controlled (1:1), multisite, subject- and observer-masked, 2-arm parallel grou...

What is the current status of trial NCT06034327?

This trial is currently recruiting. It is a NA study. The enrollment target is 150 participants. The study started on 2023-09-18. Estimated completion is 2027-03-31.

What conditions does trial NCT06034327 study?

This clinical trial studies the following conditions: Myopia, Juvenile Myopia, Myopia Progression.

What interventions are being tested in trial NCT06034327?

The interventions under investigation include: Single vision, impact-resistant spectacle lenses; Test Arm (DEVICE), Single vision, impact-resistant spectacle lenses; Control Arm (DEVICE).

Who is sponsoring clinical trial NCT06034327?

This trial is sponsored by SightGlass Vision, which has 8 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06034327 being conducted?

This trial has 14 study locations across California, Florida, Georgia, Illinois, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Myopia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06034327's enrollment target sits among peer trials

150 30th of 90 higher than 61 of 90 other Myopia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Myopia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00412594 · 150 participants · Phase 2

    Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia

  • NCT01484730 · 150 participants

    A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion

  • NCT01985919 · 150 participants

    Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples

  • NCT02016248 · 150 participants · NA

    SBRT Boost for Unfavorable Prostate Cancer'

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06034327, the US trial registry maintained by the National Library of Medicine. NCT06034327 (mid enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.